Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
Javed Butler(Jackson Memorial Hospital), Milton Packer(Baylor University Medical Center), Martina Brueckmann, Piotr Ponikowski(Wroclaw Medical University), Ola Vedin(Uppsala University), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(London School of Hygiene & Tropical Medicine), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), James L. Januzzi(Harvard University), Ileana L. Piña(American Heart Association), Muhammad Shahzeb Khan(University of Mississippi Medical Center), Carolyn S.P. Lam(University of Glasgow), Nadia Giannetti(Inserm), Naveed Sattar(University of Glasgow), Subodh Verma(St. Michael's Hospital), Barbara Peil(Boehringer Ingelheim (Germany)), João Pedro Ferreira(Inserm), Waheed Jamal(Inserm), Stefan D. Anker(Charité - Universitätsmedizin Berlin), Cordula Zeller(Inserm)
Cited by 179
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k